135 related articles for article (PubMed ID: 9676822)
21. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
Khanna S; John JP; Reddy LP
Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
[TBL] [Abstract][Full Text] [Related]
22. Hypoglossal nerve response to 5-HT3 drugs injected into the XII nucleus and vena cava in the rat.
Fenik P; Ogawa H; Veasey SC
Sleep; 2001 Dec; 24(8):871-8. PubMed ID: 11766156
[TBL] [Abstract][Full Text] [Related]
23. Neurobiology of obsessive compulsive disorder: a possible role for serotonin.
Winslow JT; Insel TR
J Clin Psychiatry; 1990 Aug; 51 Suppl():27-31; discussion 55-8. PubMed ID: 2199432
[TBL] [Abstract][Full Text] [Related]
24. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder.
Pian KL; Westenberg HG; van Megen HJ; den Boer JA
Psychopharmacology (Berl); 1998 Dec; 140(3):365-70. PubMed ID: 9877016
[TBL] [Abstract][Full Text] [Related]
25. The serotonin hypothesis of obsessive compulsive disorder.
Barr LC; Goodman WK; Price LH
Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():79-82. PubMed ID: 8201248
[TBL] [Abstract][Full Text] [Related]
26. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder.
Bastani B; Nash JF; Meltzer HY
Arch Gen Psychiatry; 1990 Sep; 47(9):833-9. PubMed ID: 2203327
[TBL] [Abstract][Full Text] [Related]
27. Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder.
Lesch KP; Hoh A; Schulte HM; Osterheider M; Müller T
Psychopharmacology (Berl); 1991; 105(3):415-20. PubMed ID: 1686817
[TBL] [Abstract][Full Text] [Related]
28. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
de Leeuw AS; Westenberg HG
J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183
[TBL] [Abstract][Full Text] [Related]
29. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
[TBL] [Abstract][Full Text] [Related]
30. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature.
Serata D; Kotzalidis GD; Rapinesi C; Janiri D; Di Pietro S; Callovini G; Piacentino D; Gasperoni C; Brugnoli R; Ferri VR; Girardi N; Tatarelli R; Ferracuti S; Angeletti G; Girardi P; Del Casale A
Hum Psychopharmacol; 2015 Mar; 30(2):70-84. PubMed ID: 25676060
[TBL] [Abstract][Full Text] [Related]
31. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
Zohar J; Mueller EA; Insel TR; Zohar-Kadouch RC; Murphy DL
Arch Gen Psychiatry; 1987 Nov; 44(11):946-51. PubMed ID: 3675134
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
Soltani F; Sayyah M; Feizy F; Malayeri A; Siahpoosh A; Motlagh I
Hum Psychopharmacol; 2010 Aug; 25(6):509-13. PubMed ID: 20737524
[TBL] [Abstract][Full Text] [Related]
33. Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls.
Hollander E; DeCaria C; Nitescu A; Cooper T; Stover B; Gully R; Klein DF; Liebowitz MR
Psychiatry Res; 1991 May; 37(2):161-77. PubMed ID: 1876628
[TBL] [Abstract][Full Text] [Related]
34. The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome.
Cath DC; Gijsman HJ; Schoemaker RC; van Griensven JM; Troost N; van Kempen GM; Cohen AF
Psychopharmacology (Berl); 1999 May; 144(2):137-43. PubMed ID: 10394994
[TBL] [Abstract][Full Text] [Related]
35. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures.
Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B
Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471
[TBL] [Abstract][Full Text] [Related]
36. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J
Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215
[TBL] [Abstract][Full Text] [Related]
37. Involvement of 5-HT2C receptors in the m-CPP-induced antinociception in mice.
Chojnacka-Wójcik E; Kłodzińska A; Dereń-Wesołek A
Pol J Pharmacol; 1994; 46(5):423-8. PubMed ID: 7894529
[TBL] [Abstract][Full Text] [Related]
38. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers.
Silverstone PH; Cowen PJ
Biol Psychiatry; 1994 Sep; 36(5):309-16. PubMed ID: 7993957
[TBL] [Abstract][Full Text] [Related]
39. Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT(1A) receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects.
Schwartz PJ; Turner EH; Garcia-Borreguero D; Sedway J; Vetticad RG; Wehr TA; Murphy DL; Rosenthal NE
Psychiatry Res; 1999 Apr; 86(1):9-28. PubMed ID: 10359479
[TBL] [Abstract][Full Text] [Related]
40. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder.
Boshuisen ML; den Boer JA
Psychopharmacology (Berl); 2000 Sep; 152(1):74-9. PubMed ID: 11041318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
